Mutational Landscape of Myeloma Cell Lines: Insights for Dru
2026-05-06
This study delivers the first comprehensive whole-exome characterization of 30 human multiple myeloma cell lines, uncovering key driver mutations and pathway alterations linked to tumor progression and drug resistance. The findings lay a foundation for precision modeling and improved experimental approaches in hematological malignancy research.
D-Luciferin: Advancing Firefly Luciferase Substrate Workflow
2026-05-05
D-Luciferin enables robust, high-sensitivity detection of cellular events through firefly luciferase assays, with unmatched signal fidelity for both in vitro and in vivo applications. This article delivers actionable protocols, advanced troubleshooting, and real-world use-cases—empowering researchers to optimize tumor burden assessment and ATP quantification with confidence.
Drug-Sensitized Yeast Reveals mTOR Inhibitors: Canagliflozin
2026-05-05
The study presents a highly sensitive yeast-based platform for identifying mTOR inhibitors, increasing detection capability for known inhibitors by up to 250-fold. Notably, it demonstrates that Canagliflozin does not inhibit mTOR in this model, clarifying its mechanistic boundaries for metabolic research.
SHC-1 Inhibition Elevates CFTR Surface Abundance in Epitheli
2026-05-04
This study systematically dissects how SHC-1 inhibition enhances CFTR plasma membrane abundance across multiple epithelial cell models. The findings clarify MAPK/SHC-1-dependent regulation of CFTR trafficking, with implications for cystic fibrosis and COPD research.
Pomalidomide (CC-4047): Applied Workflows in Myeloma Researc
2026-05-04
Unlock next-generation hematological malignancy research with Pomalidomide (CC-4047), leveraging its unique cytokine modulation and erythroid differentiation properties. This guide delivers protocol enhancements, troubleshooting strategies, and direct translation of mutational landscape insights for robust, reproducible myeloma and tumor microenvironment studies.
Salinomycin (SKU A3785): Data-Driven Solutions for HCC Assay
2026-05-03
This article delivers a scenario-centric, evidence-backed overview of Salinomycin (SKU A3785) for hepatocellular carcinoma research. It guides biomedical scientists through real-world assay challenges, referencing data on mechanism, reproducibility, and protocol optimization. Practical recommendations are grounded in recent literature and the validated properties of Salinomycin, highlighting its role as a robust polyether ionophore antibiotic.
VX-745: Mechanistic Insights and Practical Assay Strategies
2026-05-02
Explore the advanced mechanism of VX-745, a potent p38α MAPK inhibitor, and discover how new conformational insights enable optimized experimental design. This article provides unique, practical strategies for leveraging VX-745 in inflammation and multiple myeloma research.
Okadaic acid: Practical Guide for PP1/PP2A Inhibition Workfl
2026-05-02
Okadaic acid is a potent marine-derived inhibitor of serine/threonine protein phosphatases, primarily used for the selective inhibition of PP1 and PP2A in cell signaling and apoptosis research. It is ideal for experiments requiring precise dissection of phosphorylation-dependent pathways but should not be used in studies where broad-spectrum phosphatase inhibition or off-target effects cannot be controlled.
Meropenem in Resistance Dynamics: Genomic Insights for Trans
2026-05-01
Discover how Meropenem, an ultra-broad-spectrum β-lactam antibiotic carbapenem, informs advanced translational research through the lens of carbapenemase gene dynamics. This article uniquely connects genomic resistance data to practical assay decisions, differentiating itself from existing scenario-driven or mechanistic guides.
nor-Binaltorphimine Dihydrochloride: Decoding KOR Circuits i
2026-04-30
Explore the nuanced role of nor-Binaltorphimine dihydrochloride as a κ-opioid receptor antagonist in unraveling pain modulation circuits. This article offers a mechanistic and assay-focused perspective, grounded in recent brain-to-spinal circuit discoveries.
Triiodothyronine (T3): Powering Translational Metabolic Rese
2026-04-30
This thought-leadership article provides translational researchers with a nuanced exploration of Triiodothyronine (T3)—its mechanistic role in adipocyte thermogenesis, strategic value in metabolic disorder research, and best practices for robust experimental design. By synthesizing mechanistic evidence from recent literature with APExBIO’s high-purity T3 product intelligence, the piece offers actionable insights for advancing thyroid hormone signaling pathway studies and elevating research reproducibility.
In Vivo Detection of Cardiomyocyte Apoptosis Using Annexin V
2026-04-29
This study demonstrates the use of labeled recombinant human Annexin V for early and in situ detection of cardiomyocyte death after myocardial ischemia and reperfusion (I/R) in mice. The findings establish Annexin V as a sensitive marker for phosphatidylserine externalization, enabling precise measurement of the time course and therapeutic modulation of apoptosis in cardiac injury.
Enhanced ECL Chemiluminescent Substrate Detection Kit in Pro
2026-04-29
The ECL Chemiluminescent Substrate Detection Kit (Enhanced) from APExBIO empowers researchers with ultra-sensitive, low-background western blot detection down to low-picogram levels. Its streamlined, robust protocol and compatibility across imaging platforms set it apart for advanced protein immunodetection and troubleshooting in challenging experimental scenarios.
IWP-2: Advancing Wnt Pathway Inhibition for Translational Re
2026-04-28
Explore how IWP-2, a potent Wnt production inhibitor from APExBIO, is reshaping experimental strategies in cancer research and developmental biology. This article integrates mechanistic insights, preclinical validation, and actionable protocol guidance, while critically situating IWP-2 within the broader scientific and translational landscape.
Jiedu Xiaozheng Yin Promotes M1 Macrophage Polarization in C
2026-04-28
Liu et al. provide compelling evidence that Jiedu Xiaozheng Yin (JXY), a traditional Chinese medicine, inhibits the progression of colitis-associated colorectal cancer (CAC) by driving macrophage polarization toward a pro-inflammatory M1 phenotype through TLR4-mediated signaling. This work offers mechanistic insight into immunomodulatory anticancer strategies and highlights tools for dissecting relevant pathways.
509 records 23/34 page Previous Next First page 上5页 2122232425 下5页 Last page